Joseph Caster, MD
Radiation Oncology · Philadelphia, PANPI 1033470604
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $663 of the $923 with a category attached, or 71.8%. Elekta, Inc. accounts for 97.6% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2020 at $663 and has fallen 92.8% since, to $48 in 2025.
Across 8 payments — averaging $115.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Elekta, Inc.$901
- Novartis$22
Across 19 payments — averaging $52,879 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$1M
Across 5 payments — averaging $615.04 each. An ownership or investment interest held by the physician or an immediate family member.
- Digital Diagnostics Inc.$3K
What the payments were for
- Travel & lodging$66372%
- Food & beverage$26128%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Elekta, Inc. | 7 | $901 |
| Novartis | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$923 in reported general payments places this provider in the 65th percentile of 339 radiation oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 60 | $843 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Philadelphia
- Neil TaunkPhiladelphia$203K
- Wenyin ShiPhiladelphia$119K
- Kevin NeadPhiladelphia$50K
- Adam DickerPhiladelphia$46K
- Tinatin ChabrashviliPhiladelphia$39K
- Bryan PukenasPhiladelphia$36K
- Sameera KumarPhiladelphia$29K
- Joshua MeyerPhiladelphia$25K
- Abigail BermanPhiladelphia$25K
- Michelle Alonso-BasantaPhiladelphia$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.